MA33219B1 - Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation - Google Patents

Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation

Info

Publication number
MA33219B1
MA33219B1 MA34280A MA34280A MA33219B1 MA 33219 B1 MA33219 B1 MA 33219B1 MA 34280 A MA34280 A MA 34280A MA 34280 A MA34280 A MA 34280A MA 33219 B1 MA33219 B1 MA 33219B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
methods
receptor
substituted azoanthracene
azoanthracene derivatives
Prior art date
Application number
MA34280A
Other languages
Arabic (ar)
English (en)
Inventor
Adnan M M Mjalli
Christopher Behme
Daniel P Christen
Dharma Rao Polisetti
James Quada
Kalpathy Santhosh
Muralidhar Bondlela
Mustafa Guzel
Ravindra Reddy Yarragunta
Devi Reddy Gohimukkula
Robert Carl Andrews
Stephen Thomas Davis
Thomas Scott Yokum
Jennifer L R Freeman
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of MA33219B1 publication Critical patent/MA33219B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur des dérivés d'azoanthracène substitués ou sur leurs sels pharmaceutiquement acceptables, qui modulent le récepteur au GLP-1 humain et qui peuvent être utiles dans le traitement de maladies, troubles ou états dans lesquels une modulation du récepteur au GLP-1 humain est utile, tels que le diabète sucré de type 2. L'invention porte également sur des compositions pharmaceutiques comprenant ces composés et sur l'utilisation de ces composés et de ces compositions dans le traitement de telles maladies, troubles ou états dans lesquels la modulation du récepteur au GLP-1 humain est utile.
MA34280A 2009-03-30 2010-03-30 Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation MA33219B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (fr) 2009-03-30 2010-03-30 Dérivés d'azoanthracène substitués, compositions pharmaceutiques et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA33219B1 true MA33219B1 (fr) 2012-04-02

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34280A MA33219B1 (fr) 2009-03-30 2010-03-30 Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation

Country Status (17)

Country Link
US (3) US8383644B2 (fr)
EP (1) EP2413693B1 (fr)
JP (1) JP5755217B2 (fr)
KR (1) KR101732978B1 (fr)
CN (1) CN102378574B (fr)
AU (1) AU2010232750B2 (fr)
BR (1) BRPI1013579A2 (fr)
CA (1) CA2757084C (fr)
DK (1) DK2413693T3 (fr)
EA (1) EA023430B1 (fr)
ES (1) ES2553645T3 (fr)
IL (1) IL214822A (fr)
MA (1) MA33219B1 (fr)
MX (1) MX2011010347A (fr)
SG (1) SG174205A1 (fr)
TN (1) TN2011000437A1 (fr)
WO (1) WO2010114824A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2757084C (fr) 2009-03-30 2017-08-29 Transtech Pharma, Inc. Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
JP6254088B2 (ja) 2011-10-17 2017-12-27 バイオセリックス， インコーポレイテッド 置換ビアリールアルキルアミド
WO2014113357A1 (fr) * 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinaisons d'un agoniste du glp1r et de metformine, et leur utilisation pour le traitement du diabète de type 2 et d'autres troubles
CN107072970B (zh) 2014-08-29 2021-05-25 得克萨斯州大学系统董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (fr) * 2017-11-22 2019-05-31 第一三共株式会社 Composé tricyclique condensé
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
KR20260036616A (ko) * 2018-05-08 2026-03-17 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
US12611401B2 (en) 2019-05-20 2026-04-28 Pfizer Inc. Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
WO2021150645A1 (fr) * 2020-01-20 2021-07-29 Crescenta Biosciences Nouveaux composés modulateurs du métabolisme cellulaire et leurs utilisations
EP4141008A4 (fr) * 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Sel d'acide pharmaceutiquement acceptable de base libre d'agoniste du récepteur glp-1, et son procédé de préparation
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021242806A1 (fr) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Intermédiaires et procédés de préparation d'un agoniste du récepteur glp-1
US20230348412A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備（ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基）丙酸甲酯及其鹽酸鹽的方法
EP4159737A4 (fr) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation d'une base libre d'agoniste du récepteur glp-1
WO2021238965A1 (fr) 2020-05-28 2021-12-02 杭州中美华东制药有限公司 Procédé de préparation de méthyl (s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phénylpropionate et son sel
EP4159719A4 (fr) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl)
CN119930605A (zh) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
TW202227455A (zh) * 2020-09-21 2022-07-16 美商維特衛治療有限責任公司 異喹啉衍生物的無定形形式
CA3194283A1 (fr) * 2020-10-08 2022-04-14 Eli Lilly And Company Composes de 6-methoxy-3,4-dihydro-1h-isoquinoline utiles dans le traitement du diabete
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CA3200245A1 (fr) 2020-11-27 2022-06-02 Junjun Wu Derive de benzimidazole, son procede de preparation et son utilisation medicale
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
WO2022262143A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Procédé de préparation de borate de pyridine
CN117500808B (zh) * 2021-06-17 2026-03-06 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
MX2023014985A (es) 2021-06-24 2024-02-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista del receptor de glp-1 y composicion y uso del mismo.
WO2023029979A1 (fr) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Procédé de préparation d'un intermédiaire agoniste du récepteur de glp-1
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
US20250332157A1 (en) 2021-09-28 2025-10-30 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Solid composition of glp-1 receptor agonist
EP4592285A1 (fr) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Composé à cycle condensé ayant un effet agoniste du récepteur glp-1
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (fr) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Agoniste de glp-1r et son procédé thérapeutique
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (fr) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzoxazine, leur préparation et leur application
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
EP1379523B1 (fr) 2001-03-27 2005-07-27 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydro-isoquinoline en tant qu'antagonistes du recepteur de l'urotensine ii
US6933303B2 (en) 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
WO2003055482A1 (fr) * 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
AU2004224156B2 (en) * 2003-03-26 2010-08-12 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
US8466296B2 (en) * 2007-03-26 2013-06-18 Ligand Pharmaceuticals Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones
KR101616737B1 (ko) 2008-03-07 2016-05-02 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 옥사디아조안트라센 화합물
WO2009126709A1 (fr) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands pour le récepteur de glp-1 et procédés de découverte de ceux-ci
CA2757084C (fr) 2009-03-30 2017-08-29 Transtech Pharma, Inc. Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のｇｌｐ−１受容体安定化薬および調節薬

Also Published As

Publication number Publication date
CA2757084A1 (fr) 2010-10-07
AU2010232750A1 (en) 2011-09-08
AU2010232750B2 (en) 2015-10-29
US9175003B2 (en) 2015-11-03
TN2011000437A1 (en) 2013-03-27
EA201171197A8 (ru) 2014-10-30
ES2553645T3 (es) 2015-12-10
BRPI1013579A2 (pt) 2020-11-03
JP5755217B2 (ja) 2015-07-29
EP2413693A4 (fr) 2012-08-22
EA023430B1 (ru) 2016-06-30
US20130096150A1 (en) 2013-04-18
HK1164050A1 (en) 2012-09-21
CA2757084C (fr) 2017-08-29
WO2010114824A8 (fr) 2011-10-06
US20150148539A1 (en) 2015-05-28
CN102378574A (zh) 2012-03-14
US20110160198A1 (en) 2011-06-30
JP2012522060A (ja) 2012-09-20
DK2413693T3 (en) 2015-11-16
US8383644B2 (en) 2013-02-26
CN102378574B (zh) 2013-11-20
SG174205A1 (en) 2011-10-28
EA201171197A1 (ru) 2012-04-30
MX2011010347A (es) 2011-11-29
EP2413693A1 (fr) 2012-02-08
IL214822A (en) 2016-08-31
EP2413693B1 (fr) 2015-09-09
KR101732978B1 (ko) 2017-05-08
WO2010114824A1 (fr) 2010-10-07
IL214822A0 (en) 2011-11-30
US8987295B2 (en) 2015-03-24
KR20120006506A (ko) 2012-01-18

Similar Documents

Publication Publication Date Title
MA34474B1 (fr) Agonistes de gpr40
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
MA30607B1 (fr) N-phenylmethyl -5-oxo-proline-2-amides substitues tenant lieu d'antagonistes du recepteur p2x7 et procedes d'utilisation
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MA29909B1 (fr) Derives de pyridazine
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
MA30324B1 (fr) Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
MA38648A1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav